These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 25179689)

  • 21. Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population.
    Tian W; Wang Z; Zhou J; Zhang S; Wang J; Chen Q; Huang C; Pan L; Zhang L; Huang J; Shen H; Lin T
    Med Oncol; 2011 Mar; 28(1):71-8. PubMed ID: 20049561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
    Schwartzberg L; Barbour SY; Morrow GR; Ballinari G; Thorn MD; Cox D
    Support Care Cancer; 2014 Feb; 22(2):469-77. PubMed ID: 24141698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydration requirements in patients receiving highly emetogenic chemotherapy.
    Erickson R; Nebughr N; Mosier MC; Nibley W
    Future Oncol; 2019 Mar; 15(7):753-761. PubMed ID: 30499739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.
    Matsumoto K; Takahashi M; Sato K; Osaki A; Takano T; Naito Y; Matsuura K; Aogi K; Fujiwara K; Tamura K; Baba M; Tokunaga S; Hirano G; Imoto S; Miyazaki C; Yanagihara K; Imamura CK; Chiba Y; Saeki T
    Cancer Med; 2020 May; 9(10):3319-3327. PubMed ID: 32168551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer.
    Murakami M; Hashimoto H; Yamaguchi K; Yamaguchi I; Senba S; Siraishi T
    Support Care Cancer; 2014 Apr; 22(4):905-9. PubMed ID: 24240649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
    Barnes M; Calcanes G; Mosier MC; Vacirca J; Malik Z
    Am Health Drug Benefits; 2021 Dec; 14(4):133-139. PubMed ID: 35261717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
    Barnes M; Calcanes G; Mosier MC; Vacirca J; Malik Z
    Am Health Drug Benefits; 2021 Sep; 14(3):1-7. PubMed ID: 35261710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
    Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E
    Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
    Suzuki K; Yamanaka T; Hashimoto H; Shimada Y; Arata K; Matsui R; Goto K; Takiguchi T; Ohyanagi F; Kogure Y; Nogami N; Nakao M; Takeda K; Azuma K; Nagase S; Hayashi T; Fujiwara K; Shimada T; Seki N; Yamamoto N
    Ann Oncol; 2016 Aug; 27(8):1601-6. PubMed ID: 27358385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
    Schwartzberg L; Karthaus M; Rossi G; Rizzi G; Borroni ME; Rugo HS; Jordan K; Hansen V
    Cancer Med; 2019 May; 8(5):2064-2073. PubMed ID: 30968588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Di Renzo N; Montanini A; Mannina D; Dondi A; Muci S; Mancuso S; De Paolis MR; Plati C; Stelitano C; Patti C; Olivieri A; Liardo E; Buda G; Cantaffa R; Federico M
    Support Care Cancer; 2011 Oct; 19(10):1505-10. PubMed ID: 20694798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
    Kubota K; Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T
    Support Care Cancer; 2016 Sep; 24(9):4025-33. PubMed ID: 27129842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
    Karthaus M; Tibor C; Lorusso V; Singh-Arora R; Filippov A; Rizzi G; Borroni ME; Rossi G; Grunberg SM
    Support Care Cancer; 2015 Oct; 23(10):2917-23. PubMed ID: 25724407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial.
    Yu Z; Liu W; Wang L; Liang H; Huang Y; Si X; Zhang H; Liu D; Zhang H
    Support Care Cancer; 2009 Jan; 17(1):99-102. PubMed ID: 18825421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy.
    Takahashi T; Okada T; Ikejiri F; Ito S; Okada Y; Takahashi F; Kumanomido S; Jo Y; Adachi K; Onishi C; Kawakami K; Miyake T; Inoue M; Suzuki R; Suzumiya J
    Int J Clin Oncol; 2018 Feb; 23(1):189-194. PubMed ID: 28823027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
    Araz M; Karaagac M; Korkmaz L; Koral L; Inci F; Beypinar I; Uysal M; Artac M
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1091-1097. PubMed ID: 30963213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP.
    Uchida M; Mori Y; Nakamura T; Kato K; Kamezaki K; Takenaka K; Shiratsuchi M; Kadoyama K; Miyamoto T; Akashi K
    Biol Pharm Bull; 2017; 40(9):1499-1505. PubMed ID: 28867732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.